T. Goosen

发表

DMD054031 1975..1993

R. Obach, L. Di, B. Feng, 2013 .

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

B. Feng, T. Goosen, Y. Lai, 2012, Pharmaceutical Research.

Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

T. Goosen, Y. Lai, M. Varma, 2013, Pharmaceutical Research.

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

Barry C. Jones, Jeffrey R. Koup, Dennis A. Smith, 2004, Drug Metabolism and Disposition.

Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide

Jian Lin, Manthena V. S. Varma, T. Goosen, 2014, The AAPS Journal.

Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin

Jian Lin, Manthena V. S. Varma, Yurong Lai, 2013, Drug Metabolism and Disposition.

Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond

Hugh A Barton, Jian Lin, Hannah M Jones, 2013, Expert opinion on drug metabolism & toxicology.

Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid

T. Goosen, V. Sahasrabudhe, Jian Lin, 2020, CPT: pharmacometrics & systems pharmacology.

Biosynthesis and Identification of Metabolites of Maraviroc and Their Use in Experiments to Delineate the Relative Contributions of Cytochrome P4503A4 versus 3A5

G. S. Walker, R. Obach, T. Goosen, 2018, Drug Metabolism and Disposition.

Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.

A. Rowland, J. Miners, T. Goosen, 2020, Pharmacology & therapeutics.

Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats

A. D. Rodrigues, W. Humphreys, K. He, 2013, Drug Metabolism and Disposition.

Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid

Chongwoo Yu, J. Bauman, T. Goosen, 2007, Drug Metabolism and Disposition.

Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor

A. Kalgutkar, T. Goosen, M. Tu, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

Undesired versus designed enzymatic cleavage of linkers for liver targeting.

J. Bauman, T. Goosen, R. L. Dow, 2014, Bioorganic & medicinal chemistry letters.

Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases.

T. Goosen, J. Williams, P. Hollenberg, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion

B. Feng, T. Goosen, Y. Lai, 2012, Drug Metabolism and Disposition.

Elucidation of the biochemical basis for a clinical drug–drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778 875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha

A. Kalgutkar, R. Walsky, B. Feng, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”

B. Feng, T. Goosen, Y. Lai, 2013, Pharmaceutical Research.

DMD050583 966..974

T. Goosen, Y. Lai, M. Varma, 2013 .

DMD050575 906..915

A. D. Rodrigues, W. Humphreys, K. He, 2013 .

DMD057000 1163..1173

R. Walsky, T. Goosen, Jennifer J. Harris, 2014 .

Relative Contributions of Cytochrome CYP 3 A 4 Versus CYP 3 A 5 for CYP 3 A-Cleared Drugs Assessed In Vitro Using a CYP 3 A 4-Selective Inactivator ( CYP 3 cide ) s

R. Obach, R. Walsky, T. Goosen, 2014 .

Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.

Michael Z. Man, J. Paulauskis, J. Bauman, 2007, British journal of clinical pharmacology.

Effect of oral contraceptives on the transport of chlorpromazine across the CACO-2 intestinal epithelial cell line.

T. Goosen, J. Hamman, M. Chetty, 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach

R. Obach, T. Goosen, H. Eng, 2022, Drug Metabolism and Disposition.

Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator

W. S. Denney, A. Kalgutkar, J. Pfefferkorn, 2014, Drug Metabolism and Disposition.

In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes

J. Cianfrogna, T. Goosen, Jian Lin, 2020, Drug Metabolism and Disposition.

An Improved Method for Cytochrome P450 Reaction Phenotyping Using a Sequential Qualitative-Then-Quantitative Approach

R. Obach, T. Goosen, Woodrow Burchett, 2022, Drug Metabolism and Disposition.

Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1-b]thiazole-Based Inverse Agonists of the Ghrelin Receptor

G. S. Walker, A. Kalgutkar, T. Goosen, 2013, Drug Metabolism and Disposition.

Bergamottin contribution to the grapefruit juice–felodipine interaction and disposition in humans

P. Woster, T. Goosen, L. Cohen, 2004, Clinical pharmacology and therapeutics.

Microsoft Word-72067223-file00

W. Humphreys, A. D. Rodrigues, T. Goosen, 2013 .

Percutaneous Delivery of Thalidomide and Its N-Alkyl Analogs

G. Flynn, T. Goosen, C. Goosen, 2002, Pharmaceutical Research.

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Bo Feng, David B Duignan, Bruce Auerbach, 2011, Bioorganic & medicinal chemistry letters.

Intestinal targeting of drugs: rational design approaches and challenges.

T. Goosen, M. Varma, A. El‐Kattan, 2013, Current topics in medicinal chemistry.

Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity.

J. Bauman, A. Mutlib, T. Goosen, 2006, Chemical research in toxicology.

Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Screen for UGT Inhibitors

J. Bauman, R. Walsky, R. Obach, 2012, Drug Metabolism and Disposition.

Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity

T. Goosen, A. Rostami-Hodjegan, B. Achour, 2017, Drug Metabolism and Disposition.

6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1H-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to β-Estradiol

A. Kalgutkar, L. Di, T. Goosen, 2018, Drug Metabolism and Disposition.

Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)

R. Obach, R. Walsky, T. Goosen, 2014, Drug Metabolism and Disposition.

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

W. Humphreys, K. He, T. Goosen, 2010, Drug Metabolism and Disposition.

Differential effects of naturally occurring isothiocyanates on the activities of cytochrome P450 2E1 and the mutant P450 2E1 T303A.

T. Goosen, F. Chung, P. Hollenberg, 2001, Archives of biochemistry and biophysics.

Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes

A. Kalgutkar, T. Goosen, Zhiwu Lin, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs

G. S. Walker, R. Obach, R. Walsky, 2012, Drug Metabolism and Disposition.

Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants

R. Obach, T. Goosen, H. Eng, 2020, Drug Metabolism and Disposition.

In Vitro Kinetic Characterization of Axitinib Metabolism

G. S. Walker, J. Bauman, T. Goosen, 2016, Drug Metabolism and Disposition.

DMD065615 102..114

G. S. Walker, J. Bauman, T. Goosen, 2015 .

2 Running Title : In vitro metabolism of axitinib

G. S. Walker, J. Bauman, T. Goosen, 2015 .

Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance

D. Tweedie, R. Walsky, N. Hariparsad, 2018, Drug Metabolism and Disposition.

Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes

R. Obach, T. Goosen, H. Eng, 2021, Drug Metabolism and Disposition.

Identification of potent, selective, CNS-targeted inverse agonists of the ghrelin receptor.

L. Michael, T. Goosen, M. Tu, 2013, Bioorganic & medicinal chemistry letters.

Microsoft Word-75706224-file00.docx

T. Goosen, M. Varma, A. El‐Kattan, 2013 .

Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

T. Goosen, Y. Lai, M. Varma, 2013, Pharmaceutical Research.

Effects of benzyl isothiocyanate on rat and human cytochromes P450: identification of metabolites formed by P450 2B1.

T. Goosen, P. Hollenberg, D. E. Mills, 2001, The Journal of pharmacology and experimental therapeutics.

Physicochemical Characterization and Solubility Analysis of Thalidomide and Its N-Alkyl Analogs

Timothy J. Laing, G. Flynn, T. Goosen, 2004, Pharmaceutical Research.

Targeted Precise Quantification of 12 Human Recombinant Uridine-Diphosphate Glucuronosyl Transferase 1A and 2B Isoforms Using Nano-Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry with Selected Reaction Monitoring

Hendrik Neubert, T. Goosen, H. Neubert, 2013, Drug Metabolism and Disposition.

Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile.

D. Hepworth, T. Goosen, A. Shoieb, 2017, MedChemComm.

Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2).

C. C. Jorgensen, M. Boehm, D. Hepworth, 2015, Journal of medicinal chemistry.

Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring.

Hendrik Neubert, T. Goosen, H. Neubert, 2013, Journal of proteome research.

Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide

T. Goosen, M. Varma, Charles J. Rotter, 2014, The AAPS Journal.

pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.

D. B. Duignan, B. Feng, T. Goosen, 2011, Molecular pharmaceutics.

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

B. Feng, T. Goosen, Y. Lai, 2012, Pharmaceutical Research.

Investigation of CYP3A induction by PF‐05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response

T. Goosen, Zhiwu Lin, Jian Lin, 2022, Clinical and translational science.

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug‐Drug Interaction for Fesoterodine When Coadministered With Mirabegron

T. Goosen, B. Malhotra, Jian Lin, 2019, Journal of clinical pharmacology.

P190 - The effect of CYP2C9 and CYP2C19 genotype on the pharmacokinetics of PF 04965842, A JAK1 inhibitor in clinical development

J. Bauman, M. Dowty, T. Goosen, 2020 .

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans

G. S. Walker, J. Bauman, J. Telliez, 2022, Drug Metabolism and Disposition.

Data Generated by Quantitative Liquid Chromatography-Mass Spectrometry Proteomics Are Only the Start and Not the Endpoint: Optimization of Quantitative Concatemer-Based Measurement of Hepatic Uridine-5′-Diphosphate–Glucuronosyltransferase Enzymes with Reference to Catalytic Activity

T. Goosen, A. Rostami-Hodjegan, B. Achour, 2018, Drug Metabolism and Disposition.

Drug‐Drug Interaction After Single Oral Doses of the Furanocoumarin Methoxsalen and Cyclosporine

T. Goosen, M. Rheeders, M. Bouwer, 2006, Journal of clinical pharmacology.

Quantifying Warm‐Up in Showjumping Horses Over 3 Consecutive Days

V. A. Walker, D. Hodgins, T. Goosen, 2014 .

Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity

T. Goosen, A. Rostami-Hodjegan, J. Barber, 2017, Drug Metabolism and Disposition.

Chemical Stabilities and Biological Activities of Thalidomide and Its N-Alkyl Analogs

G. Flynn, T. Goosen, C. Goosen, 2002, Pharmaceutical Research.

A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development

L. Di, B. Feng, T. Goosen, 2013, Drug Metabolism and Disposition.

UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES

J. Bauman, M. Milad, T. Goosen, 2005, Drug Metabolism and Disposition.

Projections of Drug-Drug Interactions Caused by Time-Dependent Inhibitors of Cytochrome P450 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 Using In Vitro Data in Static and Dynamic Models.

T. Goosen, E. Tseng, T. J. Strelevitz, 2024, Drug metabolism and disposition: the biological fate of chemicals.

Insights into the novel hydrolytic mechanism of a diethyl 2-phenyl-2-(2-arylacetoxy)methyl malonate ester-based microsomal triglyceride transfer protein (MTP) inhibitor.

G. S. Walker, A. Kalgutkar, D. Hepworth, 2012, Chemical research in toxicology.

A. D. Rodrigues, W. Humphreys, K. He, 2013, Drug Metabolism and Disposition.

T. Goosen, H. Neubert, Philip C. Smith, 2013, Drug Metabolism and Disposition.